CNSP · CNS Pharmaceuticals, Inc. · Insider Trading

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Issued in connection with the reporting person's employment with the Company.

On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Issued in connection with the reporting person's employment with the Company.

The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Issued in connection with the reporting person's employment with the Company.

The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Issued in connection with the reporting person's employment with the Company.

The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on March 11, 2025 (the "Grant Date"), subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025.

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest as follows: 50% on the six-month anniversary of the Grant Date, 25% on the 12-month anniversary of the Grant Date, and 25% on the 18-month anniversary of the Grant Date, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

The option grant was approved by the compensation committee of CNS Pharmaceutical, Inc.'s board of directors on June 6, 2025, subject to shareholder approval of the stock option plan under which the option was granted. CNS Pharmaceutical, Inc.'s shareholders approved the plan at the company's annual meeting on November 17, 2025 (the "Shareholder Approval Date").

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in four equal quarterly installments commencing on the Shareholder Approval Date, subject to the reporting person's continued employment on each vesting date.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in 36 equal monthly installments over three years.

Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Issued in connection with the reporting person's employment with the Company.

The restricted stock units set forth in the table vest in eight equal quarterly installments over two years.

Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of the Company common stock.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of Company common stock.

Issued in connection with the reporting person's employment with the Company.

The restricted stock units set forth in the table vest in eight equal quarterly installments over two years.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

Issued in connection with the reporting person's employment with the Company.

The options set forth in the table vest in 36 equal monthly installments over three years.

The awards were issued in connection with the reporting person's Board of Director services to the Company.

The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024.

The options were issued in connection with the reporting person's Board of Director services to the Company.

The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or February 1, 2024, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date.

The stock options were issued in connection with the reporting person's Board of Director services to the Company.

The stock options set forth in this table vest in 36 equal monthly installments. The stock option was approved by the compensation committee of the company's board of directors on August 4, 2023, subject to shareholder approval of the 2020 Stock Plan under which the option was granted. The shareholders of the company approved the plan at the company's annual meeting on September 14, 2023.